Purpose: Treatment with cyclophosphamide (CYC) confers up to a 40% risk of ovarian
failure in women of reproductive age. The use of GnRH agonists (GnRHa) to preserve …

In several human malignant tumors of the urogenital tract, including cancers of the
endometrium, ovary, urinary bladder, and prostate, it has been possible to identify …

Purpose To develop guidance to practicing oncologists about available fertility preservation
methods and related issues in people treated for cancer. Methods An expert panel and a …

Gonadotropin-releasing hormone (GnRH) is the hypothalamic factor that mediates
reproductive competence. Intermittent GnRH secretion from the hypothalamus acts upon its …

Geoffrey Wingfield Harris' demonstration of hypothalamic hormones regulating pituitary
function led to their structural identification and therapeutic utilization in a wide spectrum of …

The pivotal role of gonadotropin-releasing hormone (GnRH) during the hormonal regulation
of reproductive processes is indisputable. Likewise, many factors are known to affect …

Hormonal therapy with progestins, aromatase inhibitors and gonadotropin-releasing
hormone analogues has become an effective treatment alternative to radiation and …

Vaccines have shown significant promise in eliciting protective and therapeutic responses.
However, most effective vaccines require several booster shots, and it is challenging to …

Every year, an increasing number of women with malignant and nonmalignant diseases is
successfully treated with cytotoxic chemotherapy and/or radiotherapy. Many of these …

For many years, luteinizing hormone-releasing hormone or gonadotropin-releasing
hormone (GnRH) analogs have been used to treat androgen or estrogen-dependent tumors …